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Cytomegalovirus (CMV) seropositivity is associated with
increased risk for atherosclerotic disease in patients with
end-stage renal disease. This association is due to a unique
peripheral blood CD4þ T cell population which lack CD28
(CD4þCD28 T cells). Here we found that this patient
population has a significant age-dependent increase of
CD4þCD28 T cells that comprise over half of the circulating
CD4 T cells in some. Patients over 50 years of age have a
50-fold higher percentage of CD4þCD28 T cells compared
to seronegative patients and a 5-fold higher percentage
when compared to seropositive healthy controls. Stimulation
by CMV-antigen or by polyclonal stimulation using PMA
and ionomycin showed that CD4þCD28 cells in patients
with end stage renal disease degranulated and secreted
interferon c thus indicating that they are cytolytic. The
average anti-CMV IgG titer displayed a remarkable
age-dependent increase only in patients with end stage
renal disease. These findings are highly suggestive of
repetitive antigenic stimulation of the immune system
in patients with end stage disease by subclinical CMV
reactivation which might contribute to increased
atherosclerotic risk.
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Patients with end-stage renal disease (ESRD) carry a greatly
increased risk for cardiovascular disease.1,2 Traditional risk
factors such as smoking, hypertension, and hypercholes-
terolemia can be identified, but do not explain the full
magnitude of the increment in risk.3 We have recently
showed that latency for cytomegalovirus (CMV) is an
unexpectedly high and independent risk factor for athero-
sclerosis in patients with ESRD.4 In addition, analysis of the
T-cell subsets in patients with chronic kidney disease
indicated that numbers of CMV-specific T cells increased as
the stage of renal failure progressed.5
CMV infection is unique as it leaves a clear footprint
in the T-cell repertoire. It has been estimated that on average,
as high as 10% of the circulating CD4-positive T cells
(CD4pos T cells) are CMV-specific in the latent situation.6
The phenotype of CD4-positive CMV-specific T cells is
interesting with respect to atherosclerosis, as CMV infection
increases the frequency of circulating CD4-positive CD28-
negative (CD4posCD28null) T cells.7–9
The circulating CD4posCD28null T-cell subset is enriched
in the blood of patients with acute coronary syndromes and
typically produces high levels of interferon-g (IFN-g).10
Plaque-infiltrating CD4 T cells, which are associated with
plaque vulnerability for rupture, are likely recruited from
this circulating CD4posCD28null T-cell subset.11 Apoptotic
death of smooth muscle cells may be a mechanism of plaque
destabilization, transforming stable plaques into rupture-
prone lesions. Recently, it has been shown that CD4pos
CD28null plaque-infiltrating T cells can indeed directly kill
endothelial cells and vascular smooth muscle cells by a T-cell
receptor-independent mechanism.12 These findings have
given experimental support for the pathogenetic role of this
specific T-cell subset in atherosclerotic plaque destabilization.
We hypothesized that the CD4posCD28null T-cell popu-
lation is increased in patients with ESRD compared with
healthy controls, thereby imposing a risk for plaque rupture.
Therefore, we quantified the circulating CD4posCD28null
T cells and analyzed their phenotype, expression of cytolytic
molecules, and degranulation capacity. The results show that
the presence of circulating CD4posCD28null T cells is unique
for CMV-seropositive healthy individuals and ESRD patients.
However, elderly patients with ESRD have a massively
expanded population of circulating cytolytic CD4posCD28-
null T cells. These findings may explain why CMV
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2008 International Society of Nephrology
Received 23 January 2008; revised 27 March 2008; accepted 23 April
2008; published online 9 July 2008
Correspondence: Michiel G.H. Betjes, Division of Nephrology, Department of
Internal Medicine, Erasmus Medical Center, Dr Molewater plein 40, 3015 GD
Rotterdam, The Netherlands. E-mail: M.G.H.Betjes@erasmusmc.nl
760 Kidney International (2008) 74, 760–767
seropositivity is associated with an increased risk factor for
atherosclerotic disease, especially in ESRD patients.
RESULTS
CD4posCD28null T cells are greatly expanded in
CMV-seropositive ESRD patients
In accordance with previous studies,5 the ESRD patients
showed a lower number of CD4-positive T cells compared
with healthy individuals (381 106/l versus 691 106/l,
Po0.01). The frequency of the CD4posCD28null T cells
was evidently associated with CMV infection. These cells
were rarely observed (median frequency of 0.2% of the total
CD4pos T cells) in CMV-seronegative individuals (Figure 1).
The frequency and absolute number of CD4posCD28null
T cells increased with age in CMV-seropositive individuals
(Figure 2a and b). However, these cells were greatly expanded
in CMV-seropositive ESRD patients, and comprised in some
individuals up to 65% of the total CD4pos T-cell population.
The expansion of the CD4posCD28null T-cell population
was most evident in CMV-seropositive ESRD patients over 50
years of age. Compared to age-matched seronegative ESRD
patients, they had on average a 50 times increased percentage
of CD4posCD28null T cells. Compared to elderly CMV-
seropositive healthy controls, these patients had on average
a five times increased percentage (3 versus 15% of total
CD4pos T cells) and an almost fourfold increased absolute
number of CD4posCD28null T cells (61 106/l versus
16 106/l, Po0.05).
The expansion of CD4posCD28null T cells differed sub-
stantially among ESRD patients. However, except for age, no
other demographic characteristics or clinical characteristics
(listed in Table 1), for example type of renal replacement
therapy or diabetes, were associated with the number of
CD4posCD28null T cells. Remarkably, an age-dependent
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Figure 1 | CD4posCD28null T cells and CMV seropositivity.
Percentages of CD4posCD28null T cells of the total number of
circulating CD4pos T cells, comparing CMV-seronegative to
CMV-seropositive individuals. The CMV-seronegative groups
included 30 healthy controls and 30 patients with ESRD. The
CMV-seropositive groups included 72 healthy controls and
72 ESRD patients.
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Figure 2 | CD4posCD28null T cells and age. CMV-seropositive
ESRD patients (closed symbols, N¼ 70) and age-matched healthy
controls (open symbols, N¼ 70) were divided into age groups
(p40, n¼ 9; 41–50, n¼ 17; 51–60, n¼ 18; 60–75, n¼ 26) and either
percentages (a) or absolute numbers expressed as 106/l (b) of
CD4posCD28null T cells were shown. The Bonferroni-corrected
P-value for statistical significance is Po0.006.
Table 1 | Clinical and demographic characteristics of
CMV-seropositive patients with end-stage renal disease and
CMV-seropositive healthy controls
Patients Healthy controls
Number of individuals 72 72
Age 54 (21–75)a 55 (23-71)a
Male 68.0% 27.8%**
Non-Western European origin 44.0% 30.5%
Diabetes mellitus 30.0% 0.0%**
Hypertension 84.7% 16.6%**
History of atherosclerotic disease 38.5% 0.0%**
Underlying kidney disease
Hypertensive nephropathy 31.9%
Primary glomerulopathy 20.8%
Diabetic nephropathy 18.1%
Polycystic kidney disease 11.1%
Other 13.9%
Unknown 4.2%
CMV, cytomegalovirus.[2]**P-value o0.001.
aData are given in median years with range in parentheses.
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increase of the average anti-CMV IgG titer was observed for
ESRD patients, but not for healthy individuals (Figure 3).
CD4posCD28null T cells are CCR7-negative and effector
memory cells
The expression of the CD28 molecule on the cell surface of
CD4pos T cells yields a clear distinction between a CD28pos
and CD28null population (Figure 4a). The circulating T cells
can be subdivided into naive T cells and memory T cells
by differential expression of the chemokine receptor CCR7
and CD45RO. The memory cells are able to either display
immediate effector function in inflamed tissues (effector
memory T cells (Tem)) or constitute a pool of long-lived
memory cells that develop more quickly into effector
cells following antigenic stimulation in lymphoid organs
(central memory T cells (Tcm)). More than 97% of the
CD4posCD28null T cells were CCR7 negative, with the
majority of the cells (on average 75%) expressing CD45RO,
and thus classified as classical effector memory T cells (Figure
4c and d). CD4posCD28null T cells without expression of
CD45RO were observed only in CMV-seropositive indivi-
duals, similar to the previously reported CD45RO-negative,
CMV-specific, CD8-positive effector T cells.13
Granzyme B- and perforin-positive CD4posCD28null T cells
are significantly increased in ESRD patients
Expression of the cytotoxic molecules granzyme B and
perforin was limited to the CD4posCD28null T cells (Table 2).
Specifically, the percentage of granzyme B-positive cells
within the CD4posCD28null T-cell population was higher
for ESRD patients compared with healthy individuals (65
versus 52%, Po0.01). Next, we calculated the total number
of granzyme B- and perforin-positive CD4posCD28null
T cells and the percentage of these cells in the total CD4pos
T-cell population. A significantly increased percentage and
total number of granzyme B- and percentage of perforin-
positive CD4posCD28null T cells was observed in ESRD
patients 50 years and older (Figure 5).
CD4posCD28null T cells are functional as they degranulate
and produce IFN-c after CMV-antigen and polyclonal
stimulation
Upon stimulation with CMV-antigen, the CD4posCD28null
T cells degranulated, as shown by expression of membrane-
bound CD107a, and produced IFN-g. This was observed at a
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Figure 3 | Age-related increase in CMV-specific IgG titers for
ESRD patients but not healthy controls. Mean (±s.e.m.)
CMV-specific IgG titers are depicted on the Y axis and expressed
as AU/ml, whereas on the X axis, the different age groups are
displayed. Open symbols represent the healthy controls and the
closed ones, the ESRD patients. A significant (Po0.01, Spearman’s
rank correlation coefficient) age-dependent increase was noticed
for ESRD patients (N¼ 70) but not for healthy controls (N¼ 66).
Table 2 | Percentages of T cells with cytotoxic potential and effector function in the CD4+CD28null and the CD4+CD28+ subsets
CD4+CD28null T cells CD4+CD28+ T cells
ESRD patients Healthy controls P-value1 ESRD patients Healthy controls P-value2
Number 60 60 60 60
Granzyme Ba 65.1±3.8b 51.6±4.3 0.009 4.8±1.3 1.7±0.3 0.000
Perforina 7.8±1.3 10.8±1.8 0.152 0.6±0.1 0.2±0.04 0.006
CD107a
CMV specific 1.7±0.3 1.0±0.2 0.050 0.3±0.1 0.04±0.01 0.003
PMA/ionomycin 6.5±1.4 7.6±0.4 0.671 3.5±1.0 4.2±0.9 0.396
IFN-g
CMV specific 4.7±1.0 4.1±1.3 0.175 0.6±0.2 0.2±0.04 0.338
PMA/ionomycin 65.2±5.2 36.1±8.9 0.021 21.9±3.0 12.5±2.0 0.016
CD154
CMV specific 2.7±0.7 2.7±0.9 0.319 0.4±0.2 0.2±0.03 0.496
PMA/ionomycin 3.1±0.4 3.1±0.8 0.790 11.5±2.1 12.5±2.5 0.657
CMV, cytomegalovirus; ESRD, end-stage renal disease; IFN-g, interferon-g; PMA, phorbol 12-myristate 13-acetate.[2]Data of patients with end-stage renal disease and age-
matched healthy controls are shown.
P-value1 and P-value2 for the differences between data of CD28null T cells and CD28positive cells, respectively, comparing ESRD patients with healthy controls. The
Bonferroni-corrected level of statistical significance is P-value o0.003.
aExpression determined using unstimulated PBMCs.
bData are expressed in mean percentages±standard error of the means.
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significantly lower level in the CD4posCD28pos T cells
(Table 2). After a strong polyclonal stimulus such as phorbol
12-myristate 13-acetate (PMA)/ionomycin, IFN-g produc-
tion was predominantly observed within the subset of
CD4posCD28null T cells (Table 2).
The percentages and number of CD4posCD28null T cells
expressing CD107 and IFN-g after CMV (Figure 6) or
polyclonal stimulation were significantly higher in elderly
ESRD patients, compared with the age-matched healthy
controls. The expression of CD40 ligand (CD154) after
antigenic stimulation is an important part of the co-
stimulatory pathway during antigen presentation. It can be
used as a sensitive and specific method for identifying
antigen-specific T cells.14 However, the percentage of
CD4posCD28null T cells expressing CD154 after stimulation
was always significantly lower (on average 50%) than the
percentage of IFN-g-positive cells (Table 2). This observation
indicates that CD4posCD28null T cells have become largely
independent of the CD40-CD40L co-stimulation pathway.
DISCUSSION
The CD4posCD28null circulating T-cell population has been
associated with both atherosclerotic disease and CMV
infection.6–11,15 The results of this study show that
CD4posCD28null T cells are rarely observed in CMV-
seronegative individuals, but may expand to as much as
65% of the total CD4pos T-cell population in elderly CMV-
seropositive ESRD patients. This expansion of CD4posCD28-
null T cells is in sharp contrast with the well-documented
uremia and age-related lymphopenia of the CD4pos T-cell
compartment.5,9 An age-related increased number of CMV-
specific T cells has previously been reported in healthy adults,
but only in the very elderly.9,16
The published clinical and experimental data suggest a
role for CD4posCD28null T cells in atherosclerotic plaque
destabilization,10–12 and in a previous study we found that
CMV infection was significantly and strongly associated with
atherosclerotic disease in ESRD patients.4 It is evident that
the presence of atherosclerosis is not synonymous with
plaque rupture, which may cause an acute vascular event. As
such, the present data cannot be directly correlated with the
findings of our previous clinical study.4 However, many
patients with a positive history for atherosclerotic disease
probably have experienced a plaque rupture, as they had a
history of myocardial infarction or cerebrovascular event
with known atherosclerotic plaques in the carotid artery.
Therefore, the data of the previous clinical study are not in
contradiction with the current results, but further research is
needed before it can be established that the expansion of
CD4þCD28 T cells in CMV-seropositive ESRD patients is
truly associated with plaque rupture. This study was not
designed and has not a sufficient number of patients to make
such an analysis.
The strong association between CMV infection and the
presence of CD4posCD28null T cells is in accordance with
several previous reports.7–9 Most likely the large majority of
CD4posCD28null T cells are CMV-specific, as they emerge
only after CMV infection and proliferate in response to CMV
but not to other common antigens.7 However, it cannot be
fully excluded that CD28 loss is induced on some T cells,
which are not specific for CMV peptides, due to cytokine-
mediated effects.17 Paradoxically, after CMV-specific stimula-
tion in vitro, only a minority of CD4posCD28null T cells
respond by expression of IFN-g, CD154, or CD107. This may
truly reflect a low responsiveness to antigenic stimulation,
but most likely is a consequence of the assay used, which does
not allow for detection of CMV antigens that are expressed
only during viral replication. The CMV genome encodes
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Figure 4 | CD28 expression within the different CD4pos T-cell
subsets of a CMV-seropositive individual. A representative
example of the flow cytometric analysis of CD4pos T cells for a
CMV-seropositive individual is shown in (a–c). Panel a shows a
typical example of CD28 expression within CD4-positive
peripheral blood T cells. The CD28pos (b) and CD28null
(c) CD4pos T-cell subsets are further characterized by their
expression of CD45RO and CCR7. Using these markers, the
following T-cell subsets can be discriminated: naive T cells (Tnaive,
CCR7 positive and CD45RO negative), central memory T cells
(Tcm, CCR7 positive and CD45RO positive), and effector memory
T cells (Tem, CCR7 negative and CD45RO positive). The overall
distribution of CD4posCD28null T cells of ESRD patients (n¼ 70)
and age-matched healthy controls (n¼ 66) is displayed in (d). The
Bonferroni-corrected P-value for statistical significance is Po0.02.
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many of these antigens, and by analysis of all open reading
frames it has become evident that on average as high as 10%
of all circulating CD4pos T cells are in fact CMV-specific.6
After a-specific polyclonal stimulation with PMA/ionomycin,
a much larger part of the CD4posCD28null T cells responded
with IFN-g production and degranulation, indicative of their
high cytolytic capacity.
Virtually all CD4posCD28null T cells lacked the expression
of the chemokine receptor CCR7. This receptor enables Tcm to
migrate into lymphoid structures. The Tem lack this receptor,
migrate through the tissues, and are capable of a rapid cytokine
and proliferative response. In accordance with this concept, we
found that the presence of effector molecules such as IFN-g,
granzyme B, and perforin was largely confined to the
CD4posCD28null Tem population. These phenotypical and
functional properties make CD4posCD28null T cells very well
suited for tissue invasion and subsequent destruction of target
cells. In addition, similar to CMV-specific CD8pos T cells, they
may lose CD45RO expression.13 Therefore, the CD4posCD28-
null T cells have a striking similarity to classical cytolytic CD8
T cells, a situation that seems unique for CMV infection.
ESRD patients showed a significantly higher percentage of
granzyme positivity and activation-induced degranulation
within the CD4posCD28null T-cell population. As the
expression of granzyme in CD4pos CMV-specific T cells
increases with maturation,18 this finding indicates the emer-
gence of more terminally differentiated cytolytic CD4pos-
CD28null T cells in ESRD patients, which are fully functional.
An important issue that arises from our data is the
question of why the CD4posCD28null T-cell population is so
expanded in elderly ESRD patients. We have put forward the
hypothesis that the uremia-associated immune defect causes
frequent subclinical CMV.4 There are several lines of
evidence, although indirectly, in favor of this hypothesis.
First, there are serological data that indicate frequent CMV
reactivation in ESRD patients, and even CMV organ disease
has been reported.4,19,20 In this study, we observed an age-
dependent increase of anti-CMV IgG titres in ESRD patients.
This observation is all the more remarkable as humoral
immune responses are generally depressed in ESRD patients
and supports the concept of frequent boosting of the
immune system with CMV antigens.
Second, T cells specific for herpesviruses such as CMV are
partly interleukin-7 receptor negative21 and probably depend
on frequent virus reactivation as one of the mechanisms to
sustain the CMV-specific T-cell population. Lastly, oligo-
clonic T-cell receptor usage was shown in the CD4posCD28-
null T-cell populations of patients with an increased
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Figure 5 | Cytotoxic potential of CMV-seropositive individuals. The cytotoxic potential of CD4posCD28null T cells was determined
by intracellular staining of unstimulated PBMCs with antibodies directed against granzyme B (a and c) or perforin (b and d). Percentages
(a and b) or absolute numbers (c and d) of granzyme B- or perforin-positive CD4posCD28null T are shown. The ESRD patients (n¼ 63)
and the age-matched controls (n¼ 63) were divided into a young (o50 years, n¼ 20) and elderly (X50 years, n¼ 43) group. The
Bonferroni-corrected P-value for statistical significance is Po0.007.
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frequency of these cells, indicating selective outgrowth and
propagation of CMV-specific T cells because of frequent
antigenic challenge.7,10,17
One may argue that the age-related decrease of immuno-
logical defence22 adds to the uremia-associated immune
defect, thereby increasing the incidence of subclinical CMV
reactivation. Alternatively, the constant CMV antigen-driven
proliferation in uremic patients may by itself lead to impaired
function of the immune system.23 There is little evidence to
support this concept, but it is interesting that CMV
seropositivity and antibody titre were negatively associated
with the serological response after influenza vaccination in
healthy individuals.24
In conclusion, elderly CMV-seropositive ESRD patients
are prone to a huge expansion of cytolytic CD4posCD28null
T cells that profoundly alters the composition of the CD4pos
T-cell compartment. This previously unrecognized phenom-
enon may contribute to the increased risk for atherosclerotic
disease associated with CMV seropositivity in ESRD patients.
MATERIALS AND METHODS
Study population
Patients were recruited for the study from our outpatient clinic
for renal transplantation. All patients had ESRD, defined as an
estimated glomerular filtration rate of less than 15 ml/min with or
without renal replacement therapy. Patients with a malignancy,
active infection, or taking immunosuppressive drugs were excluded.
The healthy controls were recruited from their relatives, thereby
matching for socio-economic and ethnical background. One control
per ESRD patient was chosen and in case there was the option of
more than one donor, the relative who age-matched the best was
selected for the study. The clinical and demographical data of
the CMV-seropositive patients and healthy controls are shown in
Table 1. A patient was considered to have diabetes if he or she was
taking insulin or oral hypoglycemic agents, or had previously
received such treatment and was currently using dietary modifica-
tion to control the condition. A patient was considered to have
hypertension if he or she had received the diagnosis, or was being
treated with antihypertensive medications at the time of evaluation.
All patients were carefully evaluated for the presence of athero-
sclerotic disease, using the criteria and imaging techniques as
described in detail in a recent publication.4 Healthy controls were
evaluated for the presence of atherosclerotic disease by taking their
medical history and physical examination. All controls showed
normal renal function.
All patients including healthy controls gave informed consent
and the local medical ethical committee approved the study. It was
conducted according to the Declaration of Helsinki principles and in
compliance with International Conference on Harmonization/Good
Clinical Practice regulations.
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Figure 6 | Percentages and absolute numbers of CD107a- and IFN-c-expressing CD4posCD28null T cells following CMV-antigen
stimulation. Effector functions of CD4posCD28null T cells were determined by stimulating the PBMCs for 6 h with CMV-antigen.
Percentages and absolute numbers of CD4posCD28null T cells expressing CD107a (a and c) on their cell surface or IFN-g
(b and d) intracellularly were determined using flow cytometry. The ESRD patients (n¼ 62) and the age-matched controls (n¼ 62) were
divided into a young (o50 years, n¼ 22) and elderly (X50 years, n¼ 40) group. The Bonferroni-corrected P-value for statistical significance
is Po0.007.
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Flow cytometric analysis of CD28 expression within the
different T-cell subsets
To determine the percentages and amount of various T lymphocytes,
we performed a whole-blood staining as described previously but
with some minor adjustments.5 Briefly, to examine expression of
CD28 within the various T-lymphocyte subsets, we used either
peridinin chlorophyll protein-labelled anti-CD4 or CD8 in combi-
nation with allophycocyanin-labelled anti-CD45RO (BD, Erebode-
gem, Belgium), fluorescein isothiocyanate-labelled anti-CCR7 (R&D
Systems Europe Ltd, Abingdon, UK), and phycoerythrin-labelled
anti-CD28 (BD). The various subsets are defined as CD4þ and
either naive being CCR7þ CD45RO, central memory being
CCR7þ CD45ROþ (Tcm), effector memory being CCR7
CD45ROþ (Tem), or Temra being CCR7 CD45RO. In addition,
for each of these subsets, the percentage (and amount) of cells nega-
tive and positive for CD28 was determined. Analysis was performed
using the FACS Canto II (BD) and FACSDIVA software (BD).
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated from
35 ml of heparinized venous blood samples.25 PBMCs were
resuspended in RPMI-1640 containing 10% heat-inactivated pooled
human serum and 10% dimethyl sulfoxide (Sigma-Aldrich,
Schnelldorf, Germany) and stored at –801C until further use. Before
use, PBMCs were quickly thawed in RPMI-1640 (GibcoBRL, Paisley,
Scotland) supplemented with 100 IU/ml penicillin, 100mg/ml
streptomycin, 2 mM L-glutamine, and 20% heat-inactivated ABþ
pooled human serum (standard culture medium) with DNase
(0.1 mg/ml; Roche Diagnostics GmbH, Mannheim, Germany).
Finally, the cells were resuspended in standard culture medium at
4 106/ml. Following an overnight recovery, the percentage of
viable cells was determined (always 480%) and the PBMCs were
used for the different assays.
Cytotoxic potential
Unstimulated PBMCs (2 106/ml) were analyzed for cytotoxic
potential by staining the cell surface with peridinin chlorophyll
protein-labelled anti-CD4 and fluorescein isothiocyanate-labelled
anti-CD28. Following fixation and permeabilization, cells were
subjected to intracellular staining with one of the following
phycoerythrin-labelled antibodies directed against perforin (BD)
or granzyme B (Sanquin, Amsterdam, The Netherlands). Percen-
tages of granzyme B- or perforin-positive cells were determined by
analyzing the samples using the FACSCanto II (BD), selecting cells
that have a typical lymphocyte scatter pattern, are CD4 positive, and
either lack or express CD28.
CD107a degranulation assay
This assay was described in detail previously and detects surface
mobilization of CD107a, a marker of degranulation associated with
cytolytic function.26 For this purpose, PBMCs were stimulated with
CMV lysate (30 mg/ml; Microbix Biosystems Inc., Toronto, Canada)
for 6 h, with the last 5 h in the presence of monensin (Golgistop,
BD). As a control, PBMCs were stimulated in standard culture
medium alone or using a combination of PMA (50 ng/ml) and
ionomycin (1mg/ml) (both from Sigma-Aldrich). Subsequently,
CD107a surface expression was determined by staining the cells with
peridinin chlorophyll protein-labelled anti-CD4, phycoerythrin-
labelled anti-CD28, and fluorescein isothiocyanate-labelled anti-
CD107a (BD Pharmingen, Erembodegem, Belgium) and analyzing
the samples using the FACSCanto II in a similar way as described
before. Net antigen-specific frequencies of CD107a-expressing
CD4þ T cells were determined by correcting the signal induced
by CMV-antigen or PMA/ionomycin for the background induced by
standard culture medium alone.
Intracellular cytokine staining
The intracellular cytokine assay was performed as described recently
in detail.27 Briefly, PBMCs (2 106/ml) were stimulated with either
CMV lysate for 6 h, with the last 5 h in the presence of brefeldin A
(Golgiplug, BD Pharmingen; 1 ml/106 PBMCs). As a control, PBMCs
were stimulated with standard culture medium or with a mixture of
PMA (50 ng/ml) and ionomycin (1 mg/ml). To analyze IFN-g-
producing cells, the cell surface of PBMCs was stained with
peridinin chlorophyll protein-labelled anti-CD4 and phyco-
erythrin-labelled anti-CD28. Following fixation and permeabiliza-
tion, cells were stained with fluorescein isothiocyanate-labelled
anti-IFN-g and allophycocyanin-labelled anti-CD154. Percentages
of cytokine-positive cells were determined by analyzing the
samples using the FACSCanto II (BD) as described above. To
determine the net antigen-specific frequencies of IFN-g-producing
CD4þ T cells, the signal induced by the antigen was corrected by
subtracting the background induced by standard culture medium
alone.
CMV serology
Serum IgG antibodies to CMV were measured with an enzyme
immunoassay (Biomerieux, VIDAS, Lyon, France) and expressed as
arbitrary units/ml (AU/ml). As per the manufacturer’s guidelines,
a test result exceeding 6 AU/ml was considered positive for the
presence of CMV-specific IgG antibodies.
Statistical analysis
Categorical data were analyzed by the w2-test. Differences between
groups were analyzed with the Student’s t-test when the variable was
normally distributed and otherwise by the Mann–Whitney test. The
relation between clinical parameters and T-cell characteristics was
analyzed using multivariate regression analysis. All P-values were
calculated two-sided and a P-value less than 0.05 was considered
significant. The level of statistical significance for P-values was
adjusted by a Bonferroni correction (less than 0.05 divided by the
number of comparisons) when multiple comparisons were made,
which is stated in the legends of the figures. The SPSS software
version 10.1 was used for all statistical tests.
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